Obesity Clinical Trial
Official title:
The Effect of High Intensity Interval Training and Surgical Weight Loss on Distal Symmetric Polyneuropathy Outcomes
Verified date | February 2024 |
Source | University of Michigan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to evaluate how exercise and surgical weight loss affect how likely an individual is to develop peripheral neuropathy and other neurologic complications.
Status | Active, not recruiting |
Enrollment | 140 |
Est. completion date | July 30, 2024 |
Est. primary completion date | July 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Attending a bariatric surgery clinic - BMI > 35 with one comorbid condition present or BMI > 40 without comorbid conditions present - Willing and capable to sign the Institutional Review Board (IRB) approved consent form and cooperate with the medical procedures for the study duration - Willing to accept random treatment assignment to HIIT or routine exercise counseling Exclusion Criteria: - History of distal symmetric polyneuropathy (DSP) from causes other than diabetes and/or the metabolic syndrome as determined through medical history, family history, history of medications, occupational history, history of exposure to toxins, physical and neurological examinations; - Use of warfarin, heparin, or other anticoagulants, which would increase the risk of complications from skin biopsy - Contraindication to HIIT participation including a failed exercise stress test - Participation in an experimental medication trial within 3 months of starting the study - Undergoing therapy for malignant disease other than basal-cell or squamous-cell skin cancer - Medical or psychiatric reason for not being a surgical candidate - Requiring a walking assist device; - Currently smoking |
Country | Name | City | State |
---|---|---|---|
United States | University Of Michigan | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Intraepidermal Nerve Fiber Density (IENFD) at the proximal thigh | As assessed by 3mm skin biopsies.Linear mixed effects regression modeling will account for multiple time points of the same measure. | Baseline, 3 months, 12 months and 24 months | |
Secondary | Change in Intraepidermal Nerve Fiber Density (IENFD) at distal leg. | As assessed by 3mm skin biopsies. Linear mixed effects regression modeling will account for multiple time points of the same measure. | Baseline, 3 months, 12 months and 24 months | |
Secondary | Corneal Confocal Microscopy (CCM) | Baseline, 3 month, 12 months and 24 months | ||
Secondary | 24-2 Frequency Doubling Technology (FDT) | Baseline, 3 month, 12 months and 24 months | ||
Secondary | Retinal Fundus Photography | Baseline, 3 month, 12 months and 24 months | ||
Secondary | Nerve Conduction Study (NCS) | Sural, peroneal, and tibial nerves. | Baseline and 24 months | |
Secondary | Cardiac Autonomic Neuropathy Testing | Deep breathing-E:I ratio | Baseline and 24 months | |
Secondary | Cardiac Autonomic Neuropathy Testing | Postural change-30:15 ratio | Baseline and 24 months | |
Secondary | Cardiac Autonomic Neuropathy Testing | Valsalva- Valsalva ratio | Baseline and 24 months | |
Secondary | Incidence of polyneuropathy as defined by the Toronto definition of probable neuropathy | Toronto definition of probable neuropathy-2 out of 3 of abnormal sensory examination, reflexes, and symptoms. | 24 months | |
Secondary | Michigan Neuropathy Screening Instrument (MNSI) | Baseline, 3 month, 12 months and 24 months | ||
Secondary | Utah Early Neuropathy Score | Scale 0-48, higher is more severe polyneuropathy | Baseline, 3 month, 12 months and 24 months | |
Secondary | Modified Toronto Neuropathy Score (mTNS) | Range 0-33, higher is more severe polyneuropathy | Baseline, 3 month, 12 months and 24 months | |
Secondary | Survey of Autonomic Symptoms (SAS) | Baseline, 3 month, 12 months and 24 months | ||
Secondary | Diabetic Neuropathy Score (DNS) | Range 0-4, >/=1 indicates polyneuropathy | Baseline, 3 month, 12 months and 24 months | |
Secondary | Short Form McGill Pain Questionnaire | Baseline, 3 months, 12 months, 24 months | ||
Secondary | Numerical Rating Scale for pain | Range 0-10, higher score indicates more pain | Baseline, 3 months, 12 months, 24 months | |
Secondary | Neuropathy Quality of Life (NeuroQOL) | Baseline, 3 months, 12 months, and 24 months | ||
Secondary | Berg Balance Scale | Range 0-56, higher score indicates less likely to fall | Baseline, 3 months, 12 months, and 24 months | |
Secondary | 8 Foot Get Up and Go Test | Baseline, 3 months, 12 months, and 24 months | ||
Secondary | Modified Falls Efficacy Scale | Range 0-140, higher score indicates less likely to fall | Baseline, 3 months, 12 months, and 24 months | |
Secondary | Neurothesiometer | Baseline, 3 months, 12 months, and 24 months | ||
Secondary | NIH Toolbox Cognitive Battery | Baseline and at 24 months | ||
Secondary | Rey Auditory Verbal Learning Test | Baseline and at 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |